Skip to main content

Coronavirus: Pneumonia

Question for Department of Health and Social Care

UIN HL2601, tabled on 16 March 2020

To ask Her Majesty's Government what assessment they have made of the benefits of the use of Tocilizumab in the treatment of severe cases of interstitial pneumonia linked to COVID-19 in China and Italy; and what plans they have to make that drug available on the NHS.

Answered on

31 March 2020

The Department is considering carefully all available evidence around the potential of different medicines for use in treating COVID-19. Clinical trials are being developed to assess the benefits of a number of different medicines in treating COVID-19. Further medicines may be trialled should evidence indicate to the Department that this would be an appropriate course of action. The Department, the Medicines and Healthcare products Regulatory Agency, Public Health England and the National Health Service are working together to ensure that trials can begin as soon as possible. The first trial in the United Kingdom for hospitalised patients should begin later this week.